Publication:
Rhabdomyolysis in a patient under treatment with sorafenib.

dc.contributor.authorDíaz Alcázar, María Del Mar
dc.contributor.authorCervilla Sáez de Tejada, Eloísa
dc.contributor.authorRuiz Escolano, Elena
dc.date.accessioned2023-02-08T14:39:41Z
dc.date.available2023-02-08T14:39:41Z
dc.date.issued2020
dc.description.abstractWe present a case of rhabdomyolysis related to treatment with sorafenib in a patient with multifocal hepatocellular carcinoma. Rhabdomyolysis is a severe situation and potentially fatal. There are no laboratory data that can predict this condition. Early diagnosis is essential for prognosis. Rhabdomyolysis has been described as an adverse reaction of several drugs but it is not frequently related to sorafenib.
dc.identifier.doi10.17235/reed.2020.6440/2019
dc.identifier.issn1130-0108
dc.identifier.pmid31960700
dc.identifier.unpaywallURLhttps://doi.org/10.17235/reed.2020.6440/2019
dc.identifier.urihttp://hdl.handle.net/10668/14977
dc.issue.number3
dc.journal.titleRevista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
dc.journal.titleabbreviationRev Esp Enferm Dig
dc.language.isoen
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario San Cecilio
dc.page.number243-244
dc.pubmedtypeCase Reports
dc.pubmedtypeJournal Article
dc.rights.accessRightsopen access
dc.subject.meshCarcinoma, Hepatocellular
dc.subject.meshHumans
dc.subject.meshLiver Neoplasms
dc.subject.meshPrognosis
dc.subject.meshRhabdomyolysis
dc.subject.meshSorafenib
dc.titleRhabdomyolysis in a patient under treatment with sorafenib.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number112
dspace.entity.typePublication

Files